{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:11:58Z","timestamp":1792725118604,"version":"4.5.0"},"reference-count":151,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Umm Al-Qura University, Saudi Arabia","award":["25UQU4350639GSSR01"],"award-info":[{"award-number":["25UQU4350639GSSR01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Botulinum toxin (BoNT), produced by Clostridium botulinum, has transitioned from being a lethal neurotoxin to a versatile therapeutic agent. Its ability to inhibit neurotransmitter release by targeting Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor (SNARE) proteins underpins its applications in treating conditions such as spasticity, dystonia, chronic pain, and overactive bladder. The clinical and pharmacological properties of BoNT have been extensively studied, with significant advancements in its therapeutic use, safety profile, and understanding of associated adverse effects. Objective: This comprehensive review aims to consolidate historical developments, molecular mechanisms, clinical applications, and challenges associated with BoNT, with a focus on expanding its therapeutic scope while ensuring safety and efficacy. Method: A narrative approach was used to analyze and synthesize insights from 155 references spanning experimental studies, clinical trials, and reviews. Key topics included BoNT\u2019s historical milestones, mechanisms of action, therapeutic applications, and adverse events. Findings: BoNT demonstrates remarkable efficacy in a wide range of medical and cosmetic applications. In movement disorders such as dystonia and spasticity, it reduces muscle overactivity and improves functional outcomes. In chronic pain management, including migraines and neuropathic pain, BoNT significantly alleviates symptoms by modulating neurotransmitter activity. Cosmetic use for conditions like glabellar lines and hyperhidrosis highlights its precision and safety when administered appropriately. For conditions like strabismus and blepharospasm, BoNT effectively restores muscle control, reducing involuntary contractions. In urological applications, BoNT has proven to be an effective therapy for overactive bladder, offering significant symptom relief in refractory cases. However, concerns about long-distance effects, where the toxin may spread beyond the injection site to affect distant muscles or systems, have been reported in certain high-dose or sensitive populations. These findings emphasize the importance of dose optimization and patient-specific approaches. Adverse effects such as localized pain, hematoma, dysphagia, and systemic effects, particularly in high-risk groups, underscore the need for careful monitoring. The development of immunogenicity, leading to neutralizing antibodies, remains a challenge that impacts long-term therapeutic efficacy. Emerging research on novel serotypes, including BoNT\/X, and innovations in delivery mechanisms, offer promising avenues to address current limitations. Advances in optimizing dosing regimens and refining injection techniques have also contributed to minimizing complications and improving outcomes across diverse patient populations. Conclusions: BoNT remains a cornerstone in neurology and cosmetic medicine, with its therapeutic potential still expanding. The balance between efficacy and safety, driven by innovations in formulation and application, underscores the importance of continued research. Future directions should focus on minimizing adverse effects, reducing immunogenicity, and exploring novel indications to further enhance its clinical utility.<\/jats:p>","DOI":"10.3390\/jcm14062021","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T04:29:28Z","timestamp":1742185768000},"page":"2021","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4490-889X","authenticated-orcid":false,"given":"Nahla","family":"Ayoub","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah 24375, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0031-6997(25)06852-8","article-title":"The origin, structure, and pharmacological activity of botulinum toxin","volume":"33","author":"Simpson","year":"1981","journal-title":"Pharmacol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1076\/0964-704X(200008)9:2;1-Y;FT218","article-title":"On the first systematic descriptions of botulism and botulinum toxin by Justinus Kerner (1786\u20131862)","volume":"9","author":"Erbguth","year":"2000","journal-title":"J. Hist. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.53.8.1850","article-title":"Historical aspects of botulinum toxin: Justinus Kerner (1786\u20131862) and the \u201csausage poison\u201d","volume":"53","author":"Erbguth","year":"1999","journal-title":"Neurology"},{"key":"ref_4","unstructured":"Barrett, J.E. (2004). Handbook of Experimental Pharmacology Botulinum Toxin Therapy, Springer Nature."},{"key":"ref_5","first-page":"701","article-title":"Originally published as \u201cUeber einen neuen ana\u00ebroben Bacillus und seine Beziehungen zum Botulismus\u201d in Zeitschrift f\u00fcr Hygiene und Infektionskrankheiten","volume":"26","year":"1897","journal-title":"Rev. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1076\/jhin.8.1.43.1774","article-title":"On the discovery of Clostridium botulinum","volume":"8","author":"Devriese","year":"1999","journal-title":"J. Hist. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/jb.4.5.541-553.1919","article-title":"The occurrence of Bacillus botulinus in nature","volume":"4","author":"Burke","year":"1919","journal-title":"J. Bacteriol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/infdis\/43.2.152","article-title":"Studies on botulinus toxin. 3. Acid precipitation of botulinus toxin","volume":"43","author":"Snipe","year":"1928","journal-title":"J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jama.1924.02660070011006","article-title":"Further studies on the action of botulinus toxin","volume":"83","author":"Edmunds","year":"1924","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/(SICI)1097-4598(1997)6+<129::AID-MUS9>3.0.CO;2-B","article-title":"Botulinum toxin: Historical perspective and potential new indications","volume":"20","author":"Jankovic","year":"1997","journal-title":"Muscle Nerve Off. J. Am. Assoc. Electrodiagn. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Scuderi, N., and Toth, B. (2016). Botulinum Toxin: BOTOX\u00ae. International Textbook of Aesthetic Surgery, Springer.","DOI":"10.1007\/978-3-662-46599-8"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/toxins4100913","article-title":"Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments","volume":"4","author":"Chen","year":"2012","journal-title":"Toxins"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaad.2018.11.066","article-title":"The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Therapeutic options","volume":"81","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia","volume":"16","author":"Truong","year":"2010","journal-title":"Park. Relat. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/16501970500415348","article-title":"Focal spasticity therapy with botulinum toxin: Effects on function, activities of daily living and pain in 100 adult patients","volume":"38","author":"Bergfeldt","year":"2006","journal-title":"J. Rehabil. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.31083\/j.jin2105141","article-title":"Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions","volume":"21","author":"Raciti","year":"2022","journal-title":"J. Integr. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.sc.3102070","article-title":"Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: A systematic review of effectiveness and adverse effects","volume":"45","author":"MacDonald","year":"2007","journal-title":"Spinal Cord"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1212\/WNL.46.5.1306","article-title":"Botulinum toxin type A in the treatment of upper extremity spasticity","volume":"46","author":"Simpson","year":"1996","journal-title":"Neurology"},{"key":"ref_19","first-page":"377","article-title":"Botulinum toxin for glabellar lines: A review of the efficacy and safety of currently available products","volume":"12","author":"Dessy","year":"2011","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","article-title":"What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport\u00ae","volume":"64","author":"Poewe","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/2280","article-title":"Mechanics of membrane fusion","volume":"5","author":"Rizo","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"ref_22","unstructured":"Whitcup, S.M., and Hallett, M. (2004). Botulinum Toxin Therapy. Handbook of Experimental Pharmacology, Springer."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type A and implications for toxicity","volume":"10","author":"Lacy","year":"1998","journal-title":"Nat. Struct. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Carranza, M., \u0160kerlov\u00e1, J., Lee, P.G., Zhang, J., Burgin, D., Elliott, M., Philippe, J., Donald, S., Hornby, F., and Henriksson, L. (2023). Structure and activity of botulinum neurotoxin X. bioRxiv.","DOI":"10.1101\/2023.01.11.523524"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rossetto, O., Pirazzini, M., and Montecucco, C. (2014). Botulinum neurotoxins: Genetic, structural and mechanistic insights. Nat. Rev. Microbiol., 12.","DOI":"10.1038\/nrmicro3295"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1146\/annurev-biochem-013118-111654","article-title":"Botulinum and Tetanus Neurotoxins","volume":"88","author":"Dong","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.febslet.2009.06.046","article-title":"Electric dipole reorientation in the interaction of botulinum neurotoxins with neuronal membranes","volume":"583","author":"Fogolari","year":"2009","journal-title":"FEBS Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbrc.2011.06.173","article-title":"Structural and mutational analyses of the receptor binding domain of botulinum D\/C mosaic neurotoxin: Insight into the ganglioside binding mechanism","volume":"411","author":"Nuemket","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41467-017-01534-z","article-title":"Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Stern, D., Weisemann, J., Le Blanc, A., von Berg, L., Mahrhold, S., Piesker, J., Laue, M., Luppa, P.B., Dorner, M.B., and Dorner, B.G. (2018). A lipid-binding loop of botulinum neurotoxin serotypes B, DC and G is an essential feature to confer their exquisite potency. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007048"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1523\/JNEUROSCI.1158-19.2019","article-title":"The Synaptic Vesicle Cycle Revisited: New Insights into the Modes and Mechanisms","volume":"39","author":"Chanaday","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbamem.2015.08.014","article-title":"On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments","volume":"1858","author":"Pirazzini","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.celrep.2014.08.017","article-title":"Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins","volume":"8","author":"Pirazzini","year":"2014","journal-title":"Cell Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.bcp.2015.09.023","article-title":"Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism","volume":"98","author":"Zanetti","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Rossetto, O., Pirazzini, M., Lista, F., and Montecucco, C. (2019). The role of the single interchains disulfide bond in tetanus and botulinum neurotoxins and the development of antitetanus and antibotulism drugs. Cell. Microbiol., 21.","DOI":"10.1111\/cmi.13037"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00018-013-1380-7","article-title":"The blockade of the neurotransmitter release apparatus by botulinum neurotoxins","volume":"71","author":"Pantano","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1126\/science.1214270","article-title":"Botulinum neurotoxin is shielded by NTNHA in an interlocked complex","volume":"335","author":"Gu","year":"2012","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Rossetto, O., Pirazzini, M., Fabris, F., and Montecucco, C. (2020). Botulinum Neurotoxins: Mechanism of Action Botulinum Toxin Therapy. Handbook of Experimental Pharmacology, Springer.","DOI":"10.1007\/164_2020_355"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2013.10.022","article-title":"Neurotransmitter Release: The Last Millisecond in the Life of a Synaptic Vesicle","volume":"80","year":"2013","journal-title":"Neuron"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1179\/174313209X405137","article-title":"A long-term follow-up of botulinum toxin A in cervical dystonia","volume":"31","author":"Mohammadi","year":"2009","journal-title":"Neurol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Restani, L., Giribaldi, F., Manich, M., Bercsenyi, K., Menendez, G., Rossetto, O., Caleo, M., and Schiavo, G. (2012). Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1003087"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1523\/JNEUROSCI.0375-08.2008","article-title":"Long-distance retrograde effects of botulinum neurotoxin A","volume":"28","author":"Antonucci","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1073858414524633","article-title":"More than at the Neuromuscular Synapse: Actions of Botulinum Neurotoxin A in the Central Nervous System","volume":"21","author":"Mazzocchio","year":"2015","journal-title":"Neuroscientist"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Hok, P., Veverka, T., Hlustik, P., Nevrly, M., and Kanovsky, P. (2021). The Central Effects of Botulinum Toxin in Dystonia and Spasticity. Toxins, 13.","DOI":"10.3390\/toxins13020155"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Luvisetto, S. (2020). Botulinum Toxin and Neuronal Regeneration after Traumatic Injury of Central and Peripheral Nervous System. Toxins, 12.","DOI":"10.3390\/toxins12070434"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Jiang, Y.H., Jhang, J.F., Chen, S.F., and Kuo, H.C. (2024). Real-Life Treatment Outcome of Botulinum Toxin A Injection on Overactive Bladder and Voiding Dysfunction in Patients with Central Nervous System Lesions. Toxins, 16.","DOI":"10.3390\/toxins16030123"},{"key":"ref_48","first-page":"147","article-title":"Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: A prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting","volume":"9","author":"Dowson","year":"2008","journal-title":"Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00415-008-0753-6","article-title":"Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A","volume":"255","author":"Tiple","year":"2008","journal-title":"J. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_51","first-page":"CD004315","article-title":"Botulinum toxin type B for cervical dystonia","volume":"2016","author":"Marques","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.40.8.1213","article-title":"Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis","volume":"40","author":"Greene","year":"1990","journal-title":"Neurology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1212\/WNL.50.5.1461","article-title":"Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia","volume":"50","author":"Brans","year":"1998","journal-title":"Neurology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1136\/jnnp.57.12.1535","article-title":"Optimisation of botulinum treatment for cervical and axial dystonias: Experience with a Japanese type A toxin","volume":"57","author":"Mezaki","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.40.2.277","article-title":"Botulinum toxin injections for cervical dystonia","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/mds.20024","article-title":"Treatment of cervical dystonia with botulinum toxin","volume":"19","author":"Jankovic","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5603\/PJNNS.a2020.0021","article-title":"Cervical dystonia\u2014Improving the effectiveness of botulinum toxin therapy","volume":"54","author":"Tyslerowicz","year":"2020","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A\u2014Responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"Lew","year":"1997","journal-title":"Neurology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00003495-200262040-00011","article-title":"Botulinum Toxin B","volume":"62","author":"Figgitt","year":"2002","journal-title":"Drugs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1212\/WNL.42.7.1307","article-title":"Dysphagia after botulinum toxin injections for spasmodic torticollis: Clinical and radiologic findings","volume":"42","author":"Comella","year":"1992","journal-title":"Neurology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"19","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/BMR-1999-13102","article-title":"Effective treatment of cervical dystonia with botulinum toxin: Review","volume":"3","author":"Kedlaya","year":"1999","journal-title":"J. Back Musculoskelet. Rehabil."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.870060210","article-title":"Treatment of idiopathic spasmodic torticollis with botulinum toxin A: A double-blind study on twenty-three patients","volume":"6","author":"Lorentz","year":"1991","journal-title":"Mov. Disord."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A\u2014Resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00702-021-02312-4","article-title":"Consensus guidelines for botulinum toxin therapy: General algorithms and dosing tables for dystonia and spasticity","volume":"128","author":"Dressler","year":"2021","journal-title":"J. Neural Transm."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Spiegel, L.L., Ostrem, J.L., and Bledsoe, I.O. (2020). FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins, 12.","DOI":"10.3390\/toxins12050332"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Erro, R., Picillo, M., Pellecchia, M.T., and Barone, P. (2023). Improving the Efficacy of Botulinum Toxin for Cervical Dystonia: A Scoping Review. Toxins, 15.","DOI":"10.3390\/toxins15060391"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"107251","DOI":"10.1016\/j.toxicon.2023.107251","article-title":"Basis of movement control in dystonia and why botulinum toxin should influence it?","volume":"237","author":"Shukla","year":"2024","journal-title":"Toxicon"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"de Souza, J.C.C., Falcone, A.C.M., Barbosa, R.M.G., Soares, M.C., Munhoz, R., Farah, M., Capato, T., Casagrande, S.C.B., Cordellini, M.F., and de Castro Micheli, G. (2024). Botulinum Toxin and Deep Brain Stimulation in Dystonia. Toxins, 16.","DOI":"10.3390\/toxins16060282"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11940-017-0470-5","article-title":"Botulinum Toxin Treatment in Multiple Sclerosis-a Review","volume":"19","author":"Safarpour","year":"2017","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clineuro.2010.04.010","article-title":"The place of the botulinum toxin in the management of multiple sclerosis","volume":"112","author":"Habek","year":"2010","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1007\/s00415-006-1104-0","article-title":"Botulinum toxin in multiple sclerosis","volume":"253","author":"Jost","year":"2006","journal-title":"J. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Baccouche, I., Bensmail, D., Leblong, E., Fraudet, B., Aymard, C., Quintaine, V., Pottier, S., Lansaman, T., Malot, C., and Gallien, P. (2022). Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study. Toxins, 14.","DOI":"10.3390\/toxins14090582"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00415-016-8304-z","article-title":"Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: Review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force","volume":"264","author":"Dressler","year":"2017","journal-title":"J. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Novarella, F., Carotenuto, A., Cipullo, P., Iodice, R., Cassano, E., Spiezia, A.L., Capasso, N., Petracca, M., Falco, F., and Iacovazzo, C. (2022). Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis. Toxins, 14.","DOI":"10.3390\/toxins14110774"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1469-8749.2008.03189.x","article-title":"Long-term effects of botulinum toxin A in children with cerebral palsy","volume":"51","author":"Tedroff","year":"2009","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40272-019-00344-8","article-title":"Botulinum Toxin in the Management of Children with Cerebral Palsy","volume":"21","author":"Multani","year":"2019","journal-title":"Paediatr. Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0966-6362(99)00054-5","article-title":"Recommendations for the use of botulinum toxin type A in the management of cerebral palsy","volume":"11","author":"Graham","year":"2000","journal-title":"Gait Posture"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Picelli, A., Santamato, A., Cosma, M., Baricich, A., Chisari, C., Millevolte, M., Prete, C.D., Mazzu, I., Girardi, P., and Smania, N. (2021). Early Botulinum Toxin Type A Injection for Post-Stroke Spasticity: A Longitudinal Cohort Study. Toxins, 13.","DOI":"10.3390\/toxins13060374"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.toxicon.2021.09.020","article-title":"The effectiveness of botulinum toxin on spasticity and gait of hemiplegic patients after stroke: A systematic review and meta-analysis","volume":"203","author":"Varvarousis","year":"2021","journal-title":"Toxicon"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"104682","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104682","article-title":"Botulinum Toxin Type A for Upper Limb Spasticity in Poststroke Patients: A Meta-analysis of Randomized Controlled Trials","volume":"29","author":"Jia","year":"2020","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"101222","DOI":"10.1016\/j.eclinm.2021.101222","article-title":"Comparative Effectiveness of Botulinum Toxin Injections and Extracorporeal Shockwave Therapy for Post-Stroke Spasticity: A Systematic Review and Network Meta-Analysis","volume":"43","author":"Hsu","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Palazon-Garcia, R., and Benavente-Valdepenas, A.M. (2021). Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094886"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e20702","DOI":"10.1097\/MD.0000000000020702","article-title":"Can Botulinum Toxin Type A effectively treat neuropathic pain in spinal cord injury?: A protocol of systematic review and meta-analysis","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Vacca, V., Madaro, L., De Angelis, F., Proietti, D., Cobianchi, S., Orsini, T., Puri, P.L., Luvisetto, S., Pavone, F., and Marinelli, S. (2020). Revealing the Therapeutic Potential of Botulinum Neurotoxin Type A in Counteracting Paralysis and Neuropathic Pain in Spinally Injured Mice. Toxins, 12.","DOI":"10.3390\/toxins12080491"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Baricich, A., Battaglia, M., Cuneo, D., Cosenza, L., Millevolte, M., Cosma, M., Filippetti, M., Dalise, S., Azzollini, V., and Chisari, C. (2023). Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: An observational longitudinal study. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1133390"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"51889","DOI":"10.12775\/QS.2024.15.51889","article-title":"Botulinum toxin in management of back pain","volume":"15","author":"Piotrowski","year":"2024","journal-title":"Qual. Sport"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Datta Gupta, A., Edwards, S., Smith, J., Snow, J., Visvanathan, R., Tucker, G., and Wilson, D. (2022). A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain. Toxins, 14.","DOI":"10.3390\/toxins14010036"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.toxicon.2024.107440","article-title":"Pain and Botulinum Toxin\u2014Two Off-Label Botulinum Toxin Uses","volume":"237","author":"Luis","year":"2024","journal-title":"Toxicon"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/20494637241254191","article-title":"The efficacy of botulinum toxin in neuropathic pain: A systematic review","volume":"18","author":"Oliveira","year":"2024","journal-title":"Br. J. Pain"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Poenaru, D., Sandulescu, M.I., and Cinteza, D. (2023). Pain Modulation in Chronic Musculoskeletal Disorders: Botulinum Toxin, a Descriptive Analysis. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071888"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.4111\/icu.2020.61.S1.S33","article-title":"Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis","volume":"61","author":"Chen","year":"2020","journal-title":"Investig. Clin. Urol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Hsieh, P.F., Chiu, H.C., Chen, K.C., Chang, C.H., and Chou, E.C. (2016). Botulinum toxin A for the Treatment of Overactive Bladder. Toxins, 8.","DOI":"10.3390\/toxins8030059"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/0970-1591.109975","article-title":"The use of botulinum toxin for the treatment of overactive bladder syndrome","volume":"29","author":"Orasanu","year":"2013","journal-title":"Indian J. Urol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Kepczynska, K., and Domitrz, I. (2022). Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches. Toxins, 14.","DOI":"10.3390\/toxins14090619"},{"key":"ref_99","first-page":"CD011616","article-title":"Botulinum toxins for the prevention of migraine in adults","volume":"6","author":"Herd","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1756285616677005","article-title":"Botulinum toxin in the management of chronic migraine: Clinical evidence and experience","volume":"10","author":"Escher","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_101","first-page":"CD006499","article-title":"Botulinum toxin for the treatment of strabismus","volume":"3","author":"Rowe","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_102","first-page":"CD006499","article-title":"Botulinum toxin for the treatment of strabismus","volume":"3","author":"Rowe","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Castiglione, L., Murariu, M., Boeriu, E., and Enatescu, I. (2024). Assessing Botulinum Toxin Effectiveness and Quality of Life in Axillary Hyperhidrosis: A One-Year Prospective Study. Diseases, 12.","DOI":"10.3390\/diseases12010015"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jdin.2023.12.011","article-title":"Botulinum toxin A versus microwave thermolysis for primary axillary hyperhidrosis: A randomized controlled trial","volume":"15","author":"Grove","year":"2024","journal-title":"JAAD Int."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Anton Andres, M.J., Candau Perez, E.D., and Bermejo de la Fuente, M.P. (2024). Treatment of Primary Axillary Hyperhidrosis with Two Doses of Botulinum Toxin A-Observational Study. Toxins, 16.","DOI":"10.3390\/toxins16070320"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"54770","DOI":"10.12775\/QS.2024.25.54770","article-title":"Variety of therapeutic approaches to primary hyperhidrosis (HH) and botulinum toxin priority over other treatment options in this condition\u2014A review","volume":"25","author":"Pawlak","year":"2024","journal-title":"Qual. Sport"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10103-024-04115-x","article-title":"Long-term efficacy of fractional microneedle radiofrequency versus botulinum toxin-A in primary axillary hyperhidrosis: A randomized controlled trial","volume":"39","author":"Eid","year":"2024","journal-title":"Lasers Med. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Campanati, A., Diotallevi, F., Radi, G., Martina, E., Marconi, B., Bobyr, I., and Offidani, A. (2023). Efficacy and Safety of Botulinum Toxin B in Focal Hyperhidrosis: A Narrative Review. Toxins, 15.","DOI":"10.3390\/toxins15020147"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Prodan-Barbulescu, C., Castiglione, L., Burtic, S.R., Murariu, M., Reddy, S., Rosca, O., Bratosin, F., Melania Fizedean, C., Krupyshev, P., and Enatescu, I. (2024). Longitudinal Assessment of Facial Hyperhidrosis Management: Evaluating the Utility and Quality of Life Improvements following Botulinum Toxin Injection. Toxins, 16.","DOI":"10.3390\/toxins16010059"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s13555-024-01113-3","article-title":"Botulinum Toxin A and B for Palmoplantar Hyperhidrosis","volume":"14","author":"Eilertsen","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Hast, M.A., Kong, A.M., Desai, S., Back, S., Syed, S., and Holmes, J. (2024). Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm. Toxins, 16.","DOI":"10.3390\/toxins16080362"},{"key":"ref_112","first-page":"109","article-title":"12-year effectiveness and safety of botulinum toxin type A for the treatment of blepharospasm and hemifacial spasm","volume":"25","year":"2024","journal-title":"Rev. Mex. Neurocienc."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Girard, B., Couesnon, A., Girard, E., and Molg\u00f3, J. (2024). Stable Convergent Polyneuronal Innervation and Altered Synapse Elimination in Orbicularis oculi Muscles from Patients with Blepharospasm Responding Poorly to Recurrent Botulinum Type-A Neurotoxin Injections. Toxins, 16.","DOI":"10.3390\/toxins16120506"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13760-024-02658-y","article-title":"Depressive symptoms and quality of life in patients with benign essential blepharospasm under long-term therapy with botulinum toxin","volume":"125","author":"Wabbels","year":"2025","journal-title":"Acta Neurol. Belg."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"778","DOI":"10.35755\/jmedassocthai.2024.10.778-785-897","article-title":"Efficacy and Complications of Full Dose versus Half Dose of Botulinum Toxin Type A Injection in Benign Essential Blepharospasm","volume":"107","author":"Thitiwichienlert","year":"2024","journal-title":"J. Med. Assoc. Thail."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Wang, B., Wei, X., Qi, H., Bao, X., Hu, M., and Ma, J. (2024). Efficacy and safety of botulinum neurotoxin in the treatment of hemifacial spasms: A systematic review and meta-analysis. BMC Neurol., 24.","DOI":"10.1186\/s12883-024-03883-x"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e24898","DOI":"10.1016\/j.heliyon.2024.e24898","article-title":"Factors influencing short-term prognosis after botulinum toxin type A treatment for hemifacial spasm: A retrospective study","volume":"10","author":"Tian","year":"2024","journal-title":"Heliyon"},{"key":"ref_118","first-page":"1762","article-title":"The impact of COVID-19 infection on botulinum toxin hypersensitivity: Case report and literature review","volume":"33","author":"Kubaisi","year":"2023","journal-title":"J. Pak. Assoc. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1111\/jocd.15251","article-title":"Influence of COVID-19 mRNA vaccination on the efficacy and safety of Botulinum toxin type A injections","volume":"21","author":"Mukari","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"119610","DOI":"10.1016\/j.jns.2021.119914","article-title":"Impact of COVID-19 related delays of botulinum toxin injections on the quality of life of patients with dystonia or spasticity","volume":"429","author":"Teuschl","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"105","DOI":"10.31689\/rmm.2021.29.2.105","article-title":"The COVID-19 Pandemic a Study on Its Impact on Patients with Dystonia and Related Conditions Treated with Botulinum Toxin in a Tertiary Centre in Romania","volume":"29","author":"Avasilichioaiei","year":"2022","journal-title":"Mod. Med."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Bavikatte, G., Jacinto, J., Deltombe, T., and Wissel, J. (2021). Botulinum Toxin Services for Neurorehabiliation: Recommendations for Challenges and Opportunities during the COVID-19 Pandemic. Toxins, 13.","DOI":"10.3390\/toxins13080584"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Bellows, S., and Jankovic, J. (2019). Immunogenicity Associated with Botulinum Toxin Treatment. Toxins, 11.","DOI":"10.3390\/toxins11090491"},{"key":"ref_124","first-page":"e1","article-title":"Clinical Relevance of Botulinum Toxin Immunogenicity","volume":"26","author":"Benecke","year":"2012","journal-title":"Curr. Opin."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5999\/aps.2021.00766","article-title":"Immunogenicity of botulinum toxin","volume":"49","author":"Wee","year":"2022","journal-title":"Arch. Plast. Surg."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1097\/DSS.0000000000004293","article-title":"Immunogenicity of Botulinum Toxin A: Insights","volume":"50","author":"Rahman","year":"2024","journal-title":"Dermatol. Surg."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Lee, K.W.A., Chan, L.K.W., Lee, A.W.K., Lee, C.H., Wan, J., and Yi, K.H. (2024). Immunogenicity of Botulinum Toxin Type A in Different Clinical and Cosmetic Treatment, a Literature Review. Life, 14.","DOI":"10.3390\/life14101217"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Martin, M.U., Frevert, J., and Tay, C.M. (2024). Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity. Toxins, 16.","DOI":"10.3390\/toxins16020101"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2005.06.011","article-title":"Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases","volume":"53","author":"Mohan","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1469-8749.2009.03583.x","article-title":"Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy","volume":"52","author":"Naidu","year":"2010","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1469-8749.2010.03814.x","article-title":"Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy","volume":"53","author":"Janakan","year":"2011","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/dmcn.13686","article-title":"Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections","volume":"60","author":"Swinney","year":"2018","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.3390\/toxins7114645","article-title":"Questionnaire about the adverse events and side effects following botulinum toxin A treatment in patients with cerebral palsy","volume":"7","author":"Blaszczyk","year":"2015","journal-title":"Toxins"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00128071-200506030-00001","article-title":"Managing Adverse Events Associated with Botulinum Toxin Type A","volume":"16","author":"Wollina","year":"2005","journal-title":"Am. J. Clin. Derm."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00192-014-2499-2","article-title":"Trigonal versus extratrigonal botulinum toxin-A: A systematic review and meta-analysis of efficacy and adverse events","volume":"26","author":"Davis","year":"2015","journal-title":"Int. Urogynecology J."},{"key":"ref_137","first-page":"1","article-title":"Botulinum toxin type A in scar treatment: Review article","volume":"28","author":"Baranowska","year":"2024","journal-title":"Med. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e42350","DOI":"10.1016\/j.heliyon.2025.e42350","article-title":"Pioneering Pain Management with Botulinum Toxin Type A: From Anti-Inflammation to Regenerative Therapies","volume":"11","author":"Rahmatipour","year":"2025","journal-title":"Heliyon"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jocd.15513","article-title":"Botulinum toxin for cosmetic treatments in young adults: An evidence-based review and survey on current practice among aesthetic practitioners","volume":"22","author":"Michon","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.det.2024.08.004","article-title":"Innovation in Botulinum Toxins","volume":"43","author":"Rashied","year":"2025","journal-title":"Dermatol. Clin."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Papagni, M., Renga, M., Mogavero, S., Veronesi, P., and Cavallini, M. (2025). The Esthetic Use of Botulinum Toxins in Cancer Patients: Providing a Foundation for Future Indications. Toxins, 17.","DOI":"10.3390\/toxins17010031"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1007\/s12325-021-01882-9","article-title":"Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications","volume":"38","author":"Carr","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/asj\/sjab058","article-title":"Immunogenicity to Botulinum Toxin Type A: A Systematic Review With Meta-Analysis Across Therapeutic Indications","volume":"42","author":"Rahman","year":"2022","journal-title":"Aesthet. Surg. J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e4407","DOI":"10.1097\/GOX.0000000000004407","article-title":"Emerging Trends in Botulinum Neurotoxin A Resistance: An International Multidisciplinary Review and Consensus","volume":"10","author":"Ho","year":"2022","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00702-020-02163-5","article-title":"Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: A meta-analytic study","volume":"127","author":"Siongco","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/dmcn.14874","article-title":"Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: A systematic review update and meta-analysis","volume":"63","author":"Bohn","year":"2021","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Rasera, A., Squintani, G.M., and Cerruto, M.A. (2024). A Systematic Review of Botulinum Toxin Injection in Pediatric Dystonia. Toxins, 16.","DOI":"10.3390\/toxins16070289"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e32378","DOI":"10.1097\/MD.0000000000032378","article-title":"Botulinum neurotoxins: Future innovations","volume":"102","author":"Dolly","year":"2023","journal-title":"Medicine"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Brin, M.F., Nelson, M., Ashourian, N., Brideau-Andersen, A., and Maltman, J. (2024). Update on Non-Interchangeability of Botulinum Neurotoxin Products. Toxins, 16.","DOI":"10.3390\/toxins16060266"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Kumar, R., and Singh, B.R. (2025). Botulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic Action. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020777"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Fonfria, E., Elliott, M., Beard, M., Chaddock, J.A., and Krupp, J. (2018). Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity. Toxins, 10.","DOI":"10.3390\/toxins10070278"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/2021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:54:40Z","timestamp":1760028880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,16]]},"references-count":151,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14062021"],"URL":"https:\/\/doi.org\/10.3390\/jcm14062021","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,16]]}}}